Publication type: Article in scientific journal
Type of review: Peer review (publication)
Title: Macromolecular crowding tuned extracellular matrix deposition in a bioprinted human rhabdomyosarcoma model
Authors: D'Agostino, Stefania
Rimann, Markus
Gamba, Piergiorgio
Perilongo, Giorgio
Pozzobon, Michela
Raghunath, Michael
et. al: No
DOI: 10.1016/j.bprint.2022.e00213
Published in: Bioprinting
Volume(Issue): 27
Issue: e00213
Issue Date: 30-May-2022
Publisher / Ed. Institution: Elsevier
ISSN: 2405-8866
Language: English
Subjects: Bioprinting; Rhabdomyosarcoma microenvironment; Macromolecular crowding; 3D model of rhabdomyosarcoma
Subject (DDC): 610.28: Biomedicine, biomedical engineering
Abstract: The role of the extracellular matrix (ECM) in tumor recurrence and metastasis has been gaining attention. Indeed, not only cellular, but also structural proteins influence migratory and invasive capacity of tumor cells, including growth and resistance to drugs. Therefore, new in vitro tumor models that entail improved ECM formation and deposition are needed. Here, we are developed three-dimensional (3D) models of pediatric soft tissue sarcoma (Rhabdomyosarcoma [RMS]) with the two major subgroups, the embryonal (ERMS) and the alveolar (ARMS) form. We applied macromolecular crowding (MMC) technology to monolayer cultures, spheroids, and 3D bioprinted constructs. In all culture models, exposure to MMC significantly increased ECM deposition. Interestingly, bioprinted constructs showed a collagen and fibronectin matrix architecture that was comparable to that of tumor xenografts. Furthermore, the bioprinted model not only showed tumor cell growth inside the structure but also displayed cell clusters leaving the edges of the bioprinted construct, probably emulating a metastatic mechanism. ARMS and ERMS cells reacted differently in the bioprinted structure. Indeed, the characteristic metastatic behavior was much more pronounced in the more aggressive ARMS subtype. This promising approach opens new avenues for studying RMS microenvironment and creating a platform for cancer drug testing including the native tumor ECM.
Further description: EU COST Action CA16119 CellFit
Fulltext version: Published version
License (according to publishing contract): Licence according to publishing contract
Departement: Life Sciences and Facility Management
Organisational Unit: Institute of Chemistry and Biotechnology (ICBT)
Appears in collections:Publikationen Life Sciences und Facility Management

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.